Trevena (TRVN) says FDA informed it that data were not sufficient to support continuation of previously granted Breakthrough Therapy designation for oliceridine

March 7, 2019 4:32 PM

Trevena (NASDAQ: TRVN) disclosed in an SEC filing:In February 2016, based on the preliminary evidence from Trevena’s (the “Company”) Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found